15 / 17
Is MFS a relevant endpoint?
•
19 trials (12,712 patients with non M1 prostate cancer) were analyzed to evaluate the surrogacy of MFS
for OS
•
Surrogacy independent of therapies (primary local intervention and type of adjuvant therapy)
Probability
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0.1
0
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Years From Random Assignment
MFS
OS
12,712
10,831
7656
4394
1711
668
MFS
OS
No. (%) of events of 12,712
OS: 5350 (42)
MFS: 5733 (45)
No. at risk
12,712
11,321
8162
4714
1853
726
Meta-analysis of RCTs in localized PC (ICECaP Working Group)
Xie W, et al. JCO. 2017:35;3097-104.